Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SPIN1 | Q9Y657 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12006335 | 0.93 | SIGMAR1 (0.39) | OPRD1OPRK1OPRM1SIGMAR1ACHE | |
| SCHEMBL12005744 | 0.85 | ACHE (0.44) | SIGMAR1ACHE | |
| SCHEMBL12005557 | 0.82 | WEE1 (0.38) | — | |
| SCHEMBL28813979 | 0.79 | HSD17B3 (0.35) | — | |
| SCHEMBL12005468 | 0.79 | NR1H2 (0.35) | — | |
| SCHEMBL1952271 | 0.79 | LMNA (0.33) | — | |
| SCHEMBL12006122 | 0.78 | NR1H2 (0.35) | — | |
| SCHEMBL12006482 | 0.78 | FPR1 (0.31) | — | |
| SCHEMBL7657781 | 0.77 | LMNA (0.32) | OPRM1 | |
| SCHEMBL12005725 | 0.77 | OPRM1 (0.31) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| CN-103703005-A | Tricyclic inhibitors of kinases | ABBOTT LAB | 2014-04-02 | — | — | CN | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | OPRD1 3480/4885OPRK1 1069/4885OPRM1 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.